Alireza Atri

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies
    Alireza Atri
    Department of Neurology, Massachusetts General Hospital, Boston, Mass 02114, USA
    Neurodegener Dis 10:170-4. 2012
  2. pmc A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery
    Steven D Shirk
    Department of Neurology, Massachusetts General Hospital Memory Disorders Unit, 15 Parkman Street, WACC 715, Boston, MA 02114, USA
    Alzheimers Res Ther 3:32. 2011
  3. ncbi request reprint Effective pharmacological management of Alzheimer's disease
    Alireza Atri
    Geriatric Research, Education, and Clinical Center, ENRM VA Medical Center, 200 Springs Rd, Bedford, MA 01730, USA
    Am J Manag Care 17:S346-55. 2011
  4. pmc Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials
    Alireza Atri
    Memory Disorders Unit, Massachusetts General Hospital, 15 Parkman Street, Wang Ambulatory Care Center 715, Boston, MA 02114, USA
    Arch Neurol 68:599-606. 2011
  5. pmc Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease
    Donald G McLaren
    Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
    Neurodegener Dis 9:176-86. 2012
  6. pmc Long-term course and effectiveness of combination therapy in Alzheimer disease
    Alireza Atri
    Department of Neurology and Massachusetts Alzheimer s Disease Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Alzheimer Dis Assoc Disord 22:209-21. 2008
  7. pmc Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers
    Alberto Serrano-Pozo
    Memory Disorders Unit, Department of Neurology and Massachusetts Alzheimer s Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Alzheimer Dis Assoc Disord 24:220-6. 2010
  8. ncbi request reprint Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis
    Kim A Celone
    Memory Disorders Unit, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 26:10222-31. 2006
  9. pmc The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals
    Bradford C Dickerson
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
    Cereb Cortex 19:497-510. 2009
  10. doi request reprint Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
    Susan D Rountree
    Department of Neurology, Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 9:338-45. 2013

Detail Information

Publications16

  1. pmc Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies
    Alireza Atri
    Department of Neurology, Massachusetts General Hospital, Boston, Mass 02114, USA
    Neurodegener Dis 10:170-4. 2012
    ..Randomized controlled efficacy trials (RCTs), the scientific gold standard, are required for regulatory approval of Alzheimer's disease (AD) interventions, yet provide limited information regarding real-world therapeutic effectiveness...
  2. pmc A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery
    Steven D Shirk
    Department of Neurology, Massachusetts General Hospital Memory Disorders Unit, 15 Parkman Street, WACC 715, Boston, MA 02114, USA
    Alzheimers Res Ther 3:32. 2011
    ..In addition, we aimed to provide an easily accessible method of creating norms for other clinical researchers for their own, unique data sets...
  3. ncbi request reprint Effective pharmacological management of Alzheimer's disease
    Alireza Atri
    Geriatric Research, Education, and Clinical Center, ENRM VA Medical Center, 200 Springs Rd, Bedford, MA 01730, USA
    Am J Manag Care 17:S346-55. 2011
    ....
  4. pmc Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials
    Alireza Atri
    Memory Disorders Unit, Massachusetts General Hospital, 15 Parkman Street, Wang Ambulatory Care Center 715, Boston, MA 02114, USA
    Arch Neurol 68:599-606. 2011
    ..To examine the feasibility and test-retest reliability of encoding-task functional magnetic resonance imaging (fMRI) in mild Alzheimer disease (AD)...
  5. pmc Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease
    Donald G McLaren
    Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
    Neurodegener Dis 9:176-86. 2012
    ....
  6. pmc Long-term course and effectiveness of combination therapy in Alzheimer disease
    Alireza Atri
    Department of Neurology and Massachusetts Alzheimer s Disease Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Alzheimer Dis Assoc Disord 22:209-21. 2008
    ....
  7. pmc Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers
    Alberto Serrano-Pozo
    Memory Disorders Unit, Department of Neurology and Massachusetts Alzheimer s Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Alzheimer Dis Assoc Disord 24:220-6. 2010
    ..Our findings indicate that simvastatin treatment can affect brain cholesterol metabolism within 12 weeks, but did not alter molecular indices of AD pathology during this short-term treatment...
  8. ncbi request reprint Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis
    Kim A Celone
    Memory Disorders Unit, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 26:10222-31. 2006
    ..These data may also provide functional evidence of the interaction between neocortical and medial temporal lobe pathology in early AD...
  9. pmc The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals
    Bradford C Dickerson
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
    Cereb Cortex 19:497-510. 2009
    ....
  10. doi request reprint Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
    Susan D Rountree
    Department of Neurology, Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
    Alzheimers Dement 9:338-45. 2013
    ..Long-term observational controlled studies (LTOCs) extend our understanding by providing longitudinal data across multiple stages of Alzheimer's disease (AD)...
  11. pmc Neuropsychological test performance and cognitive reserve in healthy aging and the Alzheimer's disease spectrum: a theoretically driven factor analysis
    Meghan B Mitchell
    Geriatric Research Education and Clinical Center, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Massachusetts 01730, USA
    J Int Neuropsychol Soc 18:1071-80. 2012
    ..These results provide further support for the construct validity of cognitive reserve in healthy and memory impaired older adults...
  12. ncbi request reprint Prevalence and effects of lobar microhemorrhages in early-stage dementia
    Alireza Atri
    Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
    Neurodegener Dis 2:305-12. 2005
    ..The prevalence and effects of LMH detectable by gradient echo MRI (GE-MRI) in early-stage dementia are unknown...
  13. pmc Reliability of functional magnetic resonance imaging associative encoding memory paradigms in non-demented elderly adults
    Deepti Putcha
    Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Hum Brain Mapp 32:2027-44. 2011
    ....
  14. pmc Cognitively Stimulating Activities: Effects on Cognition across Four Studies with up to 21 Years of Longitudinal Data
    Meghan B Mitchell
    Edith Nourse Rogers Memorial Veterans Hospital, Geriatric Research, Education and Clinical Center, Massachusetts General Hospital, Harvard Medical School, 200 Springs Road, Bedford, MA 01730, USA
    J Aging Res 2012:461592. 2012
    ..Results therefore suggest that change in cognitive activity from one's previous level has at least a transitory association with cognitive performance measured at the same point in time...
  15. pmc An overview of longitudinal data analysis methods for neurological research
    Joseph J Locascio
    Massachusetts Alzheimer s Disease Research Center, Dept of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass
    Dement Geriatr Cogn Dis Extra 1:330-57. 2011
    ....
  16. ncbi request reprint Scopolamine reduces persistent activity related to long-term encoding in the parahippocampal gyrus during delayed matching in humans
    Karin Schon
    Department of Psychology, Boston University, Boston, Massachusetts 02215, USA
    J Neurosci 25:9112-23. 2005
    ..The results are consistent with computational modeling data and behavioral pharmacological studies, suggesting that long-term encoding-related activity may be reduced if cholinergic receptors are blocked by scopolamine...